GET DAILY SIGNALSClene Inc. (CLNN) Holds Near $4.00 (-2.7% Over 30 Days) as NDA Filing Advances for ALS Candidate
Key Takeaways
- Clene Inc. (CLNN) is a late clinical-stage biopharmaceutical company advancing CNM-Au8, an investigational gold nanocrystal therapy for neurodegenerative diseases, with ALS as its lead indication.
- Shares traded near $4.00 in late October 2026, a modest single-digit decline of roughly 2.7% over the trailing 30 days, signaling a period of consolidation rather than a sharp directional move.
- The pivotal catalyst is regulatory: Clene submitted a New Drug Application (NDA) to the FDA in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis (ALS).
- Following a Type C meeting, the FDA indicated in May 2026 that the company's proposed neurofilament light (NfL) biomarker data "may be capable" of supporting an accelerated approval filing.
- A $4 million registered direct offering completed in September 2026 extended the company's cash runway beyond the anticipated FDA decision on NDA acceptance.
- Clene plans to begin dosing in its confirmatory Phase 3 RESTORE-ALS trial in the first quarter of 2027.
Where CLNN Stands in the Current Market
Clene Inc. (CLNN) has been trading in a relatively contained range, with shares hovering near the $4.00 level in late October 2026. Over the trailing 30 days, the stock declined roughly 2.7%, moving from a closing price near $4.10 in late September to approximately $3.99. That muted move stands in contrast to the stock's wider trading history: shares remain well below their 52-week high of $13.50 and near the lower portion of a 52-week range that spans from roughly $3.02 to $13.50.
As a clinical-stage biotechnology company, Clene's price action is driven less by quarterly fundamentals and more by regulatory milestones and financing events. The subdued 30-day performance reflects investors awaiting clarity on the FDA's review of the company's lead candidate, even as the stock has drifted lower from the $4.65 level seen in late August. I also checked this using Tickeron’s AI Pattern Search Engine to see how the stock compares to others in the industry.
Clene's Business Focus and Competitive Position
Clene Inc., based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland, is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including ALS, Parkinson's disease, and multiple sclerosis. The company specializes in clean-surfaced nanotechnology (CSN) therapeutics.
Its lead asset, CNM-Au8, is an oral suspension of catalytically active gold nanocrystals designed to restore neuronal health by supporting cellular energy production and reducing oxidative stress, targeting mitochondrial function and the NAD pathway. CNM-Au8 has received Orphan Drug Designation from the FDA for ALS. Investors follow Clene primarily for the regulatory progress of CNM-Au8, given the significant unmet medical need in ALS and the absence of broadly effective disease-modifying treatments. From what I see, this positions the company in a high-stakes but potentially high-reward area of biotech.
Recent Developments Driving the Stock
The most consequential development over the past 30 days was Clene's announcement that it submitted an NDA to the FDA seeking accelerated approval of CNM-Au8 for ALS. The filing is supported by neurofilament light (NfL) biomarker data and clinical outcomes drawn from the Phase 2 HEALEY ALS Platform Trial and its open-label extension, the Phase 2 RESCUE-ALS trial, and a National Institutes of Health-sponsored expanded access program.
This filing followed a constructive regulatory path. In May 2026, after a Type C meeting, Clene disclosed that the FDA stated the proposed data "may be capable of supporting the submission and review" of an NDA under the accelerated approval pathway and acknowledged that NfL "could potentially serve as a reasonably likely surrogate endpoint."
Financing activity also shaped sentiment. In September 2026, the company closed a $4 million registered direct offering led by its chairman, founding investor Kensington Capital Holdings, and other existing shareholders, extending its cash runway into the first quarter of 2027. This followed a January 2026 oversubscribed offering of more than $28 million. Clene reported a net loss of $13.4 million, or $1.08 per share, for the second quarter of 2026, consistent with its pre-revenue clinical-stage profile. I’m watching this closely as the regulatory timeline unfolds.
Outlook for the Rest of 2026 and Into 2027
Heading into the remainder of 2026 and early 2027, the dominant watch item is the FDA's decision on whether to accept the CNM-Au8 NDA for review and, subsequently, any Prescription Drug User Fee Act (PDUFA) action date. Acceptance and review timelines will be critical catalysts for investor sentiment.
Beyond the regulatory process, investors should monitor the initiation and enrollment of the confirmatory Phase 3 RESTORE-ALS trial, expected to begin dosing in the first quarter of 2027, as well as the company's cash position and any additional financing activity. Macroeconomic conditions affecting small-cap and pre-revenue biotechnology valuations, along with broader sector rotation in and out of healthcare, may also influence trading. While analyst consensus has leaned constructive on the name, the outcome of the FDA's review remains the key binary driver, and the stock's valuation continues to reflect substantial execution and regulatory risk.
Using AI Tools in My Analysis
When evaluating names like this, I find it helpful to layer in quantitative signals alongside the fundamental and regulatory details. One approach I have used is reviewing AI-generated trading strategies that track similar small-cap biotechs to see how they have performed across different market conditions.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.
CLNN's RSI Indicator ascending out of oversold territory
The RSI Indicator for CLNN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 41 of the 44 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on CLNN as a result. In 78 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 87%.
The Moving Average Convergence Divergence (MACD) for CLNN just turned positive on October 21, 2026. Looking at past instances where CLNN's MACD turned positive, the stock continued to rise in 41 of 45 cases over the following month. The odds of a continued upward trend are 90%.
CLNN moved above its 50-day moving average on October 27, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLNN advanced for three days, in 192 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
CLNN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLNN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for CLNN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. CLNN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-2.312) is normal, around the industry mean (1.736). P/E Ratio (-1.135) is within average values for comparable stocks, (6.461). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.458). Dividend Yield (0.000) settles around the average of (0.056) among similar stocks. CLNN's P/S Ratio (222.222) is very high in comparison to the industry average of (4.925).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLNN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a blank check company, which was created with purpose to acquire, engage in a share exchange, share reconstruct, amalgate, and purchase all substantially all of the assets of, entering into contractual arrangements
Industry FoodMajorDiversified
Advertisement